XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Revenues        
Total revenues $ 983,374 $ 929,631 $ 2,179,991 $ 1,820,795
Total cost of revenues 612,527 633,980 1,125,037 1,294,047
Gross profit 370,847 295,651 1,054,954 526,748
Operating expenses:        
Selling, general and administrative 2,983,284 3,000,208 5,616,382 6,084,557
Research and development 849,358 913,194 1,864,368 1,849,009
Total operating expenses 3,832,642 3,913,402 7,480,750 7,933,566
LOSS FROM OPERATIONS (3,461,795) (3,617,751) (6,425,796) (7,406,818)
Interest income 60,340 15,352 131,780 48,676
Transaction costs allocated to warrant liabilities   (633,198)   (633,198)
Unrealized gain on change in fair value of warrants classified as a liability 68,430 1,765,000 312,430 4,404,000
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification   (394,000)   (394,000)
Loss on issuance of warrants   (1,633,767)   (1,633,767)
Other (expense) income, net (3,095) 4,581 (23,247) (8,957)
Loss before provision for income taxes (3,336,120) (4,493,783) (6,004,833) (5,624,064)
NET LOSS (3,336,120) (4,493,783) (6,004,833) (5,624,064)
Less: Net loss attributable to noncontrolling interest 31,945 23,309 61,246 48,490
NET LOSS attributable to Applied DNA Sciences, Inc. (3,304,175) (4,470,474) (5,943,587) (5,575,574)
Deemed dividend related to warrant modifications (23,919,429) (155,330) (38,826,652) (233,087)
NET LOSS attributable to common stockholders $ (27,223,604) $ (4,625,804) $ (44,770,239) $ (5,808,661)
Net loss per share attributable to common stockholders-basic (in dollars per share) $ (15.35) $ (265.45) $ (33.82) $ (373.55)
Net loss per share attributable to common stockholders-diluted (in dollars per share) $ (15.35) $ (265.45) $ (33.82) $ (373.55)
Weighted average shares outstanding- basic (in shares) 1,773,086 17,426 1,323,913 15,550
Weighted average shares outstanding- diluted (in shares) 1,773,086 17,426 1,323,913 15,550
Product revenues        
Revenues        
Total revenues $ 548,638 $ 393,125 $ 1,044,485 $ 700,442
Total cost of revenues 367,304 340,301 631,356 622,846
Service revenues        
Revenues        
Total revenues 214,184 205,486 588,628 452,633
Clinical laboratory service revenues        
Revenues        
Total revenues 220,552 331,020 546,878 667,720
Total cost of revenues $ 245,223 $ 293,679 $ 493,681 $ 671,201